NCT03957031 (LEGACY-1) is a clinical trial in Cancer, Gastric, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia.

Who is sponsoring NCT03957031?

NCT03957031 is sponsored by Fundación para la Investigación del Hospital Clínico de Valencia.

What condition does NCT03957031 study?

NCT03957031 studies Cancer, Gastric.

Is NCT03957031 still recruiting?

NCT03957031 is currently completed. Last updated 9 May 2024.

Last reviewed 2024-05-09 · How we verify

NCT03957031: LEGACY-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gastric Cancer Risk Factors Associated With EU and CELAC Populations

Completed Last updated 9 May 2024

What this trial tests

trial in Cancer, Gastric in 1,600 participants. Completed in 31 December 2023.

Timeline

31 May 2019

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Fundación para la Investigación del Hospital Clínico de Valencia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,600
Start date	31 May 2019
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	8 locations across Netherlands, Chile, Paraguay, Mexico, Argentina, Portugal, Spain

Conditions studied

Cancer, Gastric — all drugs for Cancer, Gastric →

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Who can join

Adults 18 to 90, any sex, with Cancer, Gastric. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study uses a case-control design that examines the differences in types of exposures between cases defined with a pathological confirmation of GC diagnosis, and controls, defined as patients to whom a gastroscopy was indicated and confirmed absent of GC i

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally.
van Schooten TS, Derks S, Jiménez-Martí E, Carneiro F, et al · · 2022 · cited 9× · PMID 35692051 · DOI 10.1186/s12885-022-09689-9
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries.
Medel-Jara P, Reyes Placencia D, Fuentes-López E, Corsi O, et al · · 2024 · cited 7× · PMID 39090833 · DOI 10.1002/ueg2.12605
Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project.
Dienstmann R, Ruiz-García E, Alsina M, Ruiz-Pace F, et al · · 2025 · cited 2× · PMID 40036904 · DOI 10.1016/j.esmoop.2025.104482
Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence.
Groen-van Schooten TS, Cabeza-Segura M, Ferreira RM, Martínez-Ciarpaglini C, et al · · 2025 · PMID 40113862 · DOI 10.1038/s41416-025-02979-6

Verify or expand the search:

Other Fundación para la Investigación del Hospital Clínico de Valencia trials

Trials by the same sponsor.

NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting
NCT07291999 — Tissue Characterization in STEMI Using Cardiac MRI: a Multicenter Registry · active not recruiting
NCT06655532 — Effects of an Exercise Program in Women Over 60 yr. With HFpEF and Sarcopenia on Functional Capacity and Quality of Life · NA · not yet recruiting
NCT06578078 — A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients · Phase 3 · recruiting
NCT06578520 — Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03957031 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación para la Investigación del Hospital Clínico de Valencia
Last refreshed: 9 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03957031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing